Skip to main content
SpringerLink
Log in

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The purpose of this study was to perform exploratory relationships between the pharmacokinetics of the farnesyl transferase inhibitor, tipifarnib (R115777, Zarnestra) and allelic variants of genes coding for ATP binding-cassette transporters and drug-metabolizing enzymes. Twenty-eight patients with advanced solid tumors were treated with tipifarnib administered orally at a dose of 200 or 300 mg. Blood samples were collected for pharmacokinetics and genotyping of 10 variants in genes encoding P-glycoprotein (ABCB1), cytochrome P450 isozymes CYP3A4 and CYP3A5, and UDP glucuronosyltransferase isozyme UGT1A1. The homozygous T-allele of ABCB1*8 (1236C > T) was associated with a trend for a higher area under the curve of tipifarnib as compared to patients with only one or no variant alleles [mean (±SD), 5,303 ± 1,620 ng·h/mL vs. 3,619 ± 1,275 ng·h/mL; P = 0.047). No statistically significant differences were observed with any other genetic variant (P > 0.15). Overall, this study indicates that ABCB1 genotype might be correlated with tipifarnib pharmacokinetics, although considerable overlap in exposure measures between genotype groups was observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wright JJ, Zerivitz K, Gravell AE: Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra). Oncology (Huntingt) 16: 930–931, 935–937, 2002

    Google Scholar 

  2. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61: 131–137, 2001

    CAS  PubMed  Google Scholar 

  3. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7: 3544–3550, 2001

    CAS  PubMed  Google Scholar 

  4. Van Cutsem E, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Neumann H, Safran H, Humblet Y, Van de Velde H, Ma Y, Von Hoff D: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21: 2002, Abstract # 517

  5. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J: Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 97: 3361–3369, 2001

    Article  CAS  PubMed  Google Scholar 

  6. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O’Brien S, Garcia-Maneo G, Talpaz M, Kantarjian H: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101: 1692–1697, 2003

    Article  CAS  PubMed  Google Scholar 

  7. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH: Phase I and pharmacokinetic study of farnesyl protein in transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18: 927–941, 2000

    CAS  PubMed  Google Scholar 

  8. Crul M, De Klerk GJ, Swart M, Van’t Veer LJ, De Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, De Gast GC, Beijnen JH, Schellens JHM: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20: 2726–2735, 2002

    Article  CAS  PubMed  Google Scholar 

  9. Garner RC, Goris I, Laenen AAE, Vanhoutte E, Meuldermans W, Gregory S, Garner JV, Leong D, Whattam M, Calam A, Snel CAW: Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study—experience with 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 30: 823–830, 2002

    Article  CAS  PubMed  Google Scholar 

  10. Bohets H: An in vitro study on the microsomal cytochrome P-450 form(s) involved in the metabolism of 14C-R115777 and on the effect of R115777 on the metabolism of specific human cytochrome P-450 substrates. Janssen Research Foundation, Non-clinical Pharmacokinetics Report R115777/FK2809, June 1998

  11. Evans WE, McLeod HL: Pharmacogenomics—Drug disposition, drug targets, and side effects. N Engl J Med 348: 538–549, 2003

    CAS  PubMed  Google Scholar 

  12. Verweij J, Kehrer DFS, Planting AST, De Jonge MJA, Eskens F, Klaren A, De Heus G, Palmer PA, Bol CJ, Sparreboom A: Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 20: 2001, Abstract #319

  13. Mathijssen RHJ, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9: in press, 2003

  14. Van Schaik R, Van der Werf M, Van der Heiden IP, Dorrestein S, Brosens R, Thiadens A, Van Iperen N, Van Fessem M, Van Vliet M, De Wildt SN, Van den Anker J, Lindemans J: CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population. Clin Pharmacol Ther 73: P42, 2003, Abstract #PII-49

    Google Scholar 

  15. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, Boer A, Oostra BA: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 333: 1171–1175, 1995

    Article  CAS  PubMed  Google Scholar 

  16. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12: 437–450, 2002

    Article  CAS  PubMed  Google Scholar 

  17. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13: 89–95, 2003

    CAS  PubMed  Google Scholar 

  18. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resis Updates 266: 71–84, 2003

    Google Scholar 

  19. Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR: Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 8: 2002–2009, 2002

    CAS  PubMed  Google Scholar 

  20. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K: Effect of the mutation (C3435T) at exon 26 of the MDRI gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71: 297–303, 2002

    Article  CAS  PubMed  Google Scholar 

  21. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12: 451–457, 2002

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA

    Alex Sparreboom & Howard L. McLeod

  2. Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

    Sharon Marsh

  3. Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Ron H. J. Mathijssen & Jaap Verweij

Authors
  1. Alex Sparreboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharon Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ron H. J. Mathijssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jaap Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Howard L. McLeod
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sparreboom, A., Marsh, S., Mathijssen, R.H.J. et al. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs 22, 285–289 (2004). https://doi.org/10.1023/B:DRUG.0000026254.97350.fe

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000026254.97350.fe

Search

Navigation